More Company News

HUTCHMED

Closing of fruquintinib licence to Takeda outside China
14 Mar 2023Read More

HUTCHMED

FY22 results
28 Feb 2023Read More

HUTCHMED

Completion of enrolment in amidizalisib China Phase II registration trial in FL
27 Feb 2023Read More

HUTCHMED

Takeda licences fruquintinib ex-China development and commercial rights
23 Jan 2023Read More

HUTCHMED

NHSA agreement for Orpathys inclusion on China NRDL
18 Jan 2023Read More

HUTCHMED

Completion of enrolment of China Phase III ESLIM-01 trial of sovleplenib in primary ITP
03 Jan 2023Read More

HUTCHMED

Initiation of fruquintinib US rolling NDA submission in mCRC
19 Dec 2022Read More

HUTCHMED

Strategy to focus on late-stage pipeline regulatory approvals
15 Nov 2022Read More

HUTCHMED

Top line data from FRUTIGA China Phase III in 2L gastric cancer
14 Nov 2022Read More

HUTCHMED

Initiation of China Phase II/III of fruquintinib+ sintilimab for advanced RCC
27 Oct 2022Read More

1 2 3 4 … 14
Return to HUTCHMED
© 2019-22 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).